Changes in the microbiome in women with polycystic ovary syndrome

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.68.30-35

Keywords:

microbiome, polycystic ovary syndrome, vagina, intestine

Abstract

The gut microbiome (GM) is actively studied in terms of its impact on the development of oncological pathology, immune diseases, and metabolic disorders. Women with polycystic ovary syndrome (PCOS) have an imbalance of GM, which indirectly affects the intestinal mucosal barrier. Compared with non-obese patients and a healthy population, obese individuals with PCOS have increased numbers of Enterobacteriaceae, decreased numbers of Lactobacillus and Bifidobacterium, and changes in GM are associated with inflammation and insulin resistance.
Fecal microbiota transplantation is a new method of treating inflammatory bowel diseases. GM regulation to improve the metabolism of PCOS may be one of the potential options for the future treatment of PCOS, but the specific mechanism of its action remains to be investigated.
There is increasing evidence that probiotics, prebiotics, and synbiotics are effective treatment options for PCOS patients. Studies show that probiotics can restore the diversity of the GM of mice with PCOS, reduce the disruption of the flora and improve the reproductive function of the mice.
The altered microbiome of the lower genital tract in PCOS can cause changes that are related to hormone levels during the menstrual cycle. Studies show that the vaginal microbiome of women with PCOS differs from healthy women due to the domination of Mycoplasma, Prevotella, Gardnerella, Actinomyces, Enterococcus, and Atopobium.
The level of female sex hormones is associated with the composition of the oral cavity microbiome, which is associated with such oral pathology as periodontal disease. A study of periodontal pathogens and their prevalence in women with PCOS found that healthy women had higher levels of Peptostreptococcus and a higher percentage of women infected with Treponema denticola.
New views on the management of women with PCOS indicate the importance of considering microbiome changes and open up new therapeutic opportunities. Research in this area is still ongoing, and additional studies are needed to clarify the microbial composition in women with PCOS.

Author Biographies

V.V. Artyomenko, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department

N.M. Nastradina, Odesa National Medical University, Odesa

PhD, associate professor, Department of Obstetrics and Gynecology

H.V. Kozhukhar, Odesa National Medical University, Odesa

PhD, associate professor, Department of Obstetrics and Gynecology

References

  1. Singh, S., Pal, N., Shubham S., et al. “Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.” J Clin Med 12.4 (2023): 1454. DOI: 10.3390/jcm12041454
  2. Shaw, N., Rosenfield, R.L. “Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents.” Available from: [https:www.uptodate.com/contents/definition- clinical-features-and-differential-diagnosis-of-polycystic- ovary-syndrome-in-adolescents?search=acne&topicRef=2163 &source=see_link], last accessed May 18, 2023.
  3. Froment, P., Plotton, I., Giulivi, C., et al. “At the crossroads of fertility and metabolism: The importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism.” Hum Reprod 37.6 (2022): 1207–28. DOI: 10.1093/humrep/deac067
  4. Barber, T.M., Franks, S. “Obesity and polycystic ovary syndrome.” Clin Endocrinol 95.4 (2021): 531–41. DOI: 10.1111/cen.14421. Available from: [https:onlinelibrary.wiley.com/doi/10.1111/cen.14421].
  5. Hu, X., Guo, J., Zhao, C., et al. “The gut microbiota contributes to the development of staphylococcus aureus-induced mastitis in mice.” 14.7 (2020): 1897–910. DOI: 10.1038/s41396-020-0651-1
  6. Zhao, M.K., Jiang, G., Zhou, H., et al. “Gut microbiota: a potential target for improved cancer therapy.” J Cancer Res Clin Oncol 149.1 (2023): 541–52. DOI: 10.1007/s00432-022-04546-5
  7. Zhao, H.Y., Chen, R.F., Zheng, D.X., et al. “Modified banxia xiexin decoction ameliorates polycystic ovarian syndrome with insulin resistance by regulating intestinal microbiota.” Front Cell Infect Microbiol 12 (2022): 854796. DOI: 10.3389/fcimb.2022.854796
  8. Siddiqui, R., Makhlouf, Z., Alharbi, A.M., et al. “The gut microbiome and female health.” Biology (Basel) 11.11 (2022): 1683. DOI: 10.3390/biology11111683
  9. Gu, Y.Y., Zhou, G.N., Zhou, F.Y., et al. “Gut and vaginal microbiomes in PCOS: Implications for women’s health.” Front Endocrinol 13 (2022): 808508. DOI: 10.3389/fendo.2022.808508
  10. Zhang, M.M., Hu, R.A., Huang, Y.J., et al. “Present and future: Crosstalks between polycystic ovary syndrome and gut metabolites relating to gut microbiota.” Front Endocrinol 13 (2022): 933110. DOI: 10.3389/fendo.2022.933110
  11. Quaranta, G., Sanguinetti, M., Masucci, L. “Fecal microbiota transplantation: A potential tool for treatment of human female reproductive tract diseases.” Front Immunol 10 (2019): 2653. DOI: 10.3389/fimmu.2019.02653
  12. Roessler, J., Leistner, D.M., Landmesser, U., Haghikia, A. “Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease.” Atherosclerosis 359 (2022): 1–12. DOI: 10.1016/j.atherosclerosis.2022.08.018
  13. Liu, B., Liu, X., Liang, Z., Wang, J. “Gut microbiota in obesity.” World J Gastroenterol 27.25 (2021): 3837–50. DOI: 10.3748/wjg.v27.i25.3837
  14. Moser, B., Milligan, M.A., Dao, M.C. “The microbiota-Gut-Brain axis: Clinical applications in obesity and type 2 diabetes.” Rev Invest Clin 74.4 (2022): 302–13. DOI: 10.24875/RIC.22000197
  15. Sugawara, Y., Kanazawa, A., Aida, M., et al. “Association of gut microbiota and inflammatory markers in obese patients with type 2 diabetes mellitus: Post hoc analysis of a synbiotic interventional study.” Biosci Microbiot Food Health 41.3 (2022): 103–11. DOI: 10.12938/bmfh.2021-081
  16. Duan, L.Y., An, X.D., Zhang, Y.H., et al. “Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.” BioMed Pharmacother 142 (2021): 112094. DOI: 10.1016/j.biopha.2021.112094
  17. Lin, W., Wen, L.Y., Wen, J.P., Xiang, G.D. “Effects of sleeve gastrectomy on fecal gut microbiota and short-chain fatty acid content in a rat model of polycystic ovary syndrome.” Front Endocrinol 12 (2021): 747888. DOI: 10.3389/fendo.2021.747888
  18. Lindheim, L., Bashir, M., Munzker, J., et al. “Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study.” PloS One 12.1 (2017): e0168390. DOI: 10.1371/journal.pone.0168390
  19. Zhou, L., Ni, Z., Cheng, W., et al. “Characteristic gut microbiota and predicted metabolic functions in women with PCOS.” Endocr Connect 9.1 (2020): 63–73. DOI: 10.1530/EC-19-0522
  20. Zeng, B., Lai, Z., Sun, L., et al. “Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study.” Res Microbiol 170.1 (2019): 43–52. DOI: 10.1016/j.resmic.2018.09.002
  21. Qi, X., Yun, C., Pang, Y., Qiao, J. “The impact of the gut microbiota on the reproductive and metabolic endocrine system.” Gut Microbes 13.1 (2021): 1–21. DOI: 10.1080/19490976.2021.1894070
  22. Szukiewicz, D., Trojanowski, S., Kociszewska, A., Szewczyk, G. “Modulation of the inflammatory response in polycystic ovary syndrome (PCOS)-searching for epigenetic factors.” Int J Mol Sci 23.23 (2022): 14663. DOI: 10.3390/ijms232314663
  23. Li, M.W., Chi, X.W., Wang, Y., et al. “Trends in insulin resistance: insights into mechanisms and therapeutic strategy.” Signal Transduct Tar 7.1 (2022): 216. DOI: 10.1038/s41392-022-01073-0
  24. Petrillo, T., Semprini, E., Tomatis, V., et al. “Putative complementary compounds to counteract insulin- resistance in PCOS patients.” Biomedicines 10.8 (2022): 1924. DOI: 10.3390/biomedicines10081924
  25. Amisi, C.A. “Markers of insulin resistance in polycystic ovary syndrome women: An update.” World J Diabetes 13.3 (2022): 129–49. DOI: 10.4239/wjd.v13.i3.129
  26. Qi, X., Yun, C., Liao, B., et al. “The therapeutic effect of interleukin-22 in high androgen- induced polycystic ovary syndrome.” J Endocrinol 245.2 (2020): 281–9. DOI: 10.1530/JOE-19-0589
  27. Qi, X., Yun, C., Sun, L., et al. “Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome.” Nat Med 25.8 (2019): 1225–33. DOI: 10.1038/s41591-019-0509-0
  28. Witchel, S.F., Azziz, R., Oberfield, S.E. “History of polycystic ovary syndrome, premature adrenarche, and hyperandrogenism in pediatric endocrinology.” Horm Res Paediat 95.6 (2022): 557–67. DOI: 10.1159/000526722
  29. Torres, P.J., Ho, B.S., Arroyo, P., et al. “Exposure to a healthy gut microbiome protects against reproductive and metabolic dysregulation in a PCOS mouse model.” Endocrinology 160.5 (2019): 1193–204. DOI: 10.1210/en.2019-00050
  30. Zhang, F.F., Mao, T., Cui, P., et al. “Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of Diane-35, probiotics, and berberine.” Front Microbiol 10 (2019): 175. DOI: 10.3389/fmicb.2019.00175
  31. Markle, M.E. “Polycystic ovary syndrome: implications for the advanced practice nurse in primary care.” J Am Acad Nurse Pract 13.4 (2001): 160–3. DOI: 10.1111/j.1745-7599.2001.tb00240.x
  32. Escobar-Morreale, H.F., Luque-Ramirez, M., Gonzalez, F. “Circulating inflammatory markers in polycystic ovary syndrome: A systematic review and metaanalysis.” Fertil Steril 95.3 (2011): 1048–58. DOI: 10.1016/j.fertnstert.2010.11.036
  33. Tedesco, S., Adorni, M.P., Ronda, N., et al. “Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients.” Endocrine 66.2 (2019): 360–9. DOI: 10.1007/s12020-019-01911-2
  34. Yang, Y.Q., Xia, J., Yang, Z., et al. “The abnormal level of HSP70 is related to Treg/Th17 imbalance in PCOS patients.” J Ovarian Res 14.1 (2021): 155. DOI: 10.1186/s13048-021-00867-0
  35. Nasri, F., Doroudchi, M., Jahromi, B.N., Gharesi-Fard, B. “T Helper cells profile and CD4(+)CD25(+)Foxp3(+)Regulatory T cells in polycystic ovary syndrome.” Iran J Immunol 15 (2018): 175–85. DOI: 10.22034/IJI.2018.39387
  36. Hamamah, S., Gheorghita, R., Lobiuc, A., et al. “Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols.” Front Med (Lausanne) 9 (2022): 1060581. DOI: 10.3389/fmed.2022.1060581
  37. Guo, Y.J., Qi, Y., Yang, X.F., et al. “Association between polycystic ovary syndrome and gut microbiota.” PloS One 11.4 (2016): e0153196. DOI: 10.1371/journal.pone.0153196
  38. Corrie, L., Gulati, M., Vishwas, S., et al. “Combination therapy of curcumin and fecal microbiota transplant: Potential treatment of polycystic ovarian syndrome.” Med Hypotheses 154 (2021): 110644. DOI: 10.1016/j.mehy.2021.110644
  39. Li, J., Zheng, R.Q., Lin, Z.X., et al. “Impact of Chinese herbal medicine on glucolipid metabolic outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.” Evid-Based Compl Alt 2022 (2022): 3245663. DOI: 10.1155/2022/3245663
  40. Zhu, Y., Li, Y., Liu, M., et al. “Chinese Herbal medicine, ameliorates insulin sensitivity in PCOS model rats with insulin resistance via remodeling intestinal homeostasis.” Front Endocrinol 11 (2020): 575. DOI: 10.3389/fendo.2020.00575
  41. Liu, M., Zhu, H.Q., Zhu, Y., Hu, X.D. “Guizhi fuling wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway.” J Ethnopharmacol 270 (2021): 113821. DOI: 10.1016/j.jep.2021.113821
  42. Zhao, C., Hu, X., Bao, L., et al. “Aryl hydrocarbon receptor activation by lactobacillus reuteri tryptophan metabolism alleviates escherichia coli-induced mastitis in mice.” PloS Pathog 17.7 (2021): e1009774. DOI: 10.1371/journal.ppat.1009774
  43. Miao, C., Guo, Q., Fang, X., et al. “Effects of probiotic and synbiotic supplementation on insulin resistance in women with polycystic ovary syndrome: A meta- analysis.” J Int Med Res 49.7 (2021): 3000605211031758. DOI: 10.1177/03000605211031758
  44. Li, T., Zhang, Y., Song, J., et al. “Yogurt enriched with inulin ameliorated reproductive functions and regulated gut microbiota in dehydroepiandrosterone- induced polycystic ovary syndrome mice.” Nutrients 14.2 (2022): 279. DOI: 10.3390/nu14020279
  45. Yde, C.C., Jensen, H.M., Christensen, N., et al. “Polydextrose with and without bifidobacterium animalis ssp. lactis 420 drives the prevalence of akkermansia and improves liver health in a multi-compartmental obesogenic mice study.” PloS One 16.12 (2021): e0260765. DOI: 10.1371/journal.pone.0260765
  46. Fettweis, J.M., Serrano, M.G., Brooks, J.P., et al. “The vaginal microbiome and preterm birth.” Nat Med 25.6 (2019):1012–21. DOI: 10.1038/s41591-019-0450-2
  47. Łaniewski, P., Barnes, D., Goulder, A., et al. “Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.” Sci Rep 8.1 (2018): 7593. DOI: 10.1038/s41598-018-25879-7
  48. Nené, N.R., Reisel, D., Leimbach, A., et al. “Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.” Lancet Oncol 20.8 (2019): 1171–82. DOI: 10.1016/S1470-2045(19)30340-7
  49. Hong, X., Qin, P., Huang, K., et al. “Association between polycystic ovary syndrome and the vaginal microbiome: a case-control study.” Clin Endocrinol 93 (2020): 52–60. DOI: 10.1111/cen.14198
  50. Amabebe, E., Anumba, D.O.C. “The Vaginal Microenvironment: The Physiologic Role of Lactobacilli.” Front Med (Lausanne) 5 (2018): 181. DOI: 10.3389/fmed.2018.00181
  51. Sanders, D.J., Inniss, S., Sebepos-Rogers, G., et al. “The role of the microbiome in gastrointestinal inflammation.” Biosci Rep 41.6 (2021): BSR20203850. DOI: 10.1042/BSR20203850

Downloads

Published

2023-06-30

How to Cite

Artyomenko, V., Nastradina, N., & Kozhukhar, H. (2023). Changes in the microbiome in women with polycystic ovary syndrome: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (68), 30–35. https://doi.org/10.18370/2309-4117.2023.68.30-35

Issue

No. 68 (2023)

Section

Gynecology

License

Copyright (c) 2023 В.В. Артьоменко, Н.М. Настрадіна, Г.В. Кожухар

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.